Nous utilisons des cookies pour vous proposer des contenus et services adaptés. En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies.
Ce site respecte la loi RGPD du 25 mai 2018. Pour en savoir plus, cliquez ici
The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings.
Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even life-threatening. Prompt recognition and effective management are vital. [lire la suite]
Although dopaminergic medication is the most effective treatment for patients with Parkinson’s disease (PD), its long-term use is associated with debilitating motor fluctuations. Patients may not spontaneously seek assistance when fluctuations develop, so strategies need to be put in place to identify and alleviate motor dysfunction. [lire la suite]
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. [lire la suite]